Thirteen years to get from b to a: one of the neglected isoforms of IL-37 enters the stage-Reference-Cited by-同舟云学术

Thirteen years to get from b to a: one of the neglected isoforms of IL-37 enters the stage

Published:2023-12-18 Issue:2 Volume:21 Page:201-202
ISSN:2042-0226
Container-title:Cellular & Molecular Immunology
language:en
Short-container-title:Cell Mol Immunol

Author:

Cho Steven X.,Rudloff Ina^ORCID,Ellisdon Andrew M.,Nold-Petry Claudia A.,Nold Marcel F.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Link

https://www.nature.com/articles/s41423-023-01111-z.pdf

Reference12 articles.

1. Rudloff I, Cho SX, Lao JC, Ngo D, McKenzie M, Nold-Petry CA, et al. Monocytes and dendritic cells are the primary sources of interleukin 37 in human immune cells. J Leukoc Biol. 2017;101:901–11. https://doi.org/10.1189/jlb.3MA0616-287R.

2. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11:1014–22. https://doi.org/10.1038/ni.1944.

3. Nold-Petry CA, Lo CY, Rudloff I, Elgass KD, Li S, Gantier MP, et al. IL-37 requires the receptors IL-18Ralpha and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol. 2015;16:354–65. https://doi.org/10.1038/ni.3103.

4. Openshaw PH. F1000Prime recommendations for [Nold MF et al. Nat Immunol. 2010;11:1014–22]. 2011 Available from: https://facultyopinions.com/prime/5675956.

5. Bujotzek A, Tiefenthaler G, Lariviere L, D’Andrea L, Marquez EA, Rudloff I, et al. Protein engineering of a stable and potent anti-inflammatory IL-37-Fc fusion with enhanced therapeutic potential. Cell Chem Biol. 2022;29:586–96.e4. https://doi.org/10.1016/j.chembiol.2021.10.004.